Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. is the next best biotech stock on our list.

TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target. The firm said the upcoming VIKTORIA-1 trial readout for Celcuity’s gedatolisib could act as a positive catalyst for mutant-selective inhibitors such as RLAY’s zovegalisib. Oppenheimer expects the VIKTORIA-1 results to fall short of expectations. He noted that anything below a “teenage” median progression-free survival for the gedatolisib triplet would establish a competitive benchmark that RLAY’s zovegalisib-based regimen could surpass.

Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors

Regarding Zovegalisib, Relay Therapeutics, Inc. (NASDAQ:RLAY) presented a subset of results from interim clinical data for the drug at the 2025 San Antonio Breast Cancer Symposium on December 12, 2025. Zovegalisib and fulvestrant together produced a median progression-free survival of 11.4 months in second-line patients in the ReDiscover first-in-human trial. Despite substantial prior treatment, efficacy was consistent across several patient subgroups.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company using advanced computational and experimental technologies to accelerate drug discovery. Its Dynamo platform targets previously intractable protein targets to develop small-molecule therapies, primarily in precision oncology and genetic diseases.

While we acknowledge the risk and potential of RLAY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RLAY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.